Abstract
A subset of high-risk neuroblastoma patients who have a poor end of Induction response may benefit from receiving chemoimmunotherapy, as bridge therapy, prior to Consolidation. Prospective studies evaluating this therapeutic approach and improved identification of biomarkers of response are warranted.